Anti-Cancer Studies Of β-Caryophyllene, A Natural Component Isolated From Aquilaria Crassna On Colorectal Cancer by Sabbar Dahham, Saad
  
ANTI-CANCER STUDIES OF 
β-CARYOPHYLLENE, A NATURAL 
COMPONENT ISOLATED FROM AQUILARIA 
CRASSNA ON COLORECTAL CANCER 
 
 
by 
 
 
 
 
 
SAAD SABBAR DAHHAM  
 
 
 
 
 
 
Thesis submitted in fulfillment of the requirements  
for the degree of 
Doctor of Philosophy  
 
 
October 2016 
  
 
 
 
 
This thesis is dedicated to 
 my people in Iraq who have 
long been suffering from the war 
 
ii 
 
ACKNOWLEDGEMENT 
 
Praise to Allah, The Most Gracious, The Most Merciful. I thank Him for giving 
me the auspices and strength to finish this work. 
Thereafter, first and foremost, I would like to express my sincere gratitude for my 
supervisor, Assoc. Prof. Amin Malik Shah Abdul Majid for his encouragement, constant 
guidance and patience during the four academic years of my doctoral studies. I 
appreciate his support and that he provided me the freedom to grow as an individual, 
perform effective critical thinking, and lay my own experimental design. This has 
helped me become an independent scientist. I would also like to extend my special 
thanks to my co-supervisor, Dr. Aman S. Abdul Majid, for he has guided me generously 
during my studies.  
Special thanks go to my former and present lab members, Ahmed Ibrahim, Loiy 
Elsir Ahmed Hassan, Yasser M. Tabana, Fouad S. R. al-Suede, Muhammad Asif, 
Suzana binti Hashim and Norshirin Idris for their support and assistance. My deepest 
gratitude goes to Dr. Mohamed Khadeer Ahamed Basheer, who offered invaluable input 
regarding the animal models used in this work. I would also like to sincerely thank Dr. 
Muhammad A. Iqbal for performing structural elucidation. Special thanks to Dr Nik 
Noriman Zulkepli and Mr Adil Saad for providing the plant materials. I am also 
thankful for many of the acadimic and non-academic staff members at School of 
Pharmaceutical Sciences (USM) who were generous with their support and assistance, 
Mr. Roseli, Mr. Fisal and Mr. Shanmugan. I would also like to thank Eman-
Biodiscovery and NatureCeuticals Company for using the fluorescent microscopy and 
fluorescent moleculer tomography (FMT).   
iii 
 
I will be forever thankful for my wonderful parents, Sabbar and Sumaya, my 
beloved wife, Amnah, and my grandfather, Dahham for their unconditional love and 
prayers. Their support has inspired my success. My utmost gratitude goes to my 
siblings, Omar, Mohammed, Rokiah, Maryam, Kawthar and Israa for their endless 
support.  
Last but not the least; I thank the Institute of Postgraduate Studies (IPS) at 
Universiti Sains Malaysia for awarding me USM Postgraduate Fellowship and, more 
recently, IPS conference grant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
TABLES OF CONTENTS 
ACKNOWLEDGEMENT ii 
TABLES OF CONTENTS iv 
TABLE OF FIGURES xii 
LIST OF TABLES xv 
LIST OF ABBREVIATIONS xvi 
ABSTRAK xx 
ABSTRACT xxiii 
CHAPTER ONE: INTRODUCTION  1 
1.1 Cancer biology 1 
1.2 Hallmarks of cancer 2 
1.2.1 Sustaining proliferative signalling 4 
1.2.2 Evading growth suppressors 4 
1.2.3 Resisting cell death 5 
1.2.4 Enabling replicative immortality 6 
1.2.5 Inducing angiogenesis 7 
1.2.6 Tissue invasion and metastasis 7 
1.2.7 Genomic instability and mutations 8 
1.2.8 Tumor-promoting inflammation 9 
1.3 Angiogenesis 10 
1.3.1 Pathological angiogenesis 11 
       1.3.1(a) Sprouting angiogenesis 11 
       1.3.1(b) Intussusceptive angiogenesis 12 
       1.3.3(c) Vasculogenic mimicry 14 
       1.3.3(d) Vascular co-option 14 
v 
 
1.3.4 Vascular endothelial growth factor (VEGF) 14 
1.3.5 Antiangiogenic therapy 16 
1.3.6 Mechanisms of antiangiogenic therapy 17 
       1.3.6(a) Anti-VEGF monoclonal antibodies 18 
       1.3.6(b) Small molecule inhibitors 18 
       1.3.6(c) VEGF-Trap 20 
1.4 Cell Death 20 
1.4.1 Apoptosis 21 
1.4.2 Morphological and biochemical features of apoptosis 23 
1.4.3 Apoptosis mechanism 26 
       1.4.3(a) Intrinsic pathway 26 
       1.4.3(b) Extrinsic pathway 27 
1.4.4 Apoptotic signaling pathways 30 
       1.4.4(a) Caspases pathway 30 
       1.4.4(b) p53 Pathway 31 
       1.4.4(c) TRAIL pathway 31 
       1.4.4(d) Survivin pathway 32 
1.5 Colorectal Cancer 33 
1.5.1 Burden of CRC 36 
1.5.2 Current treatment approaches for CRC 37 
1.6 Natural product 39 
1.6.1 Drug discovery from medicinal plant 40 
1.6.2 Essential oils of aromatic plants 42 
1.6.3 Agarwood from Aqularia 45 
1.6.4 Aquilaria crassna 47 
vi 
 
       1.6.4(a) Description of the plant 47 
       1.6.4(b) Taxonomic hierarchy of A. crassna 48 
       1.6.4(c) Phytochemical and pharmacological properties 50 
1.7 Rationale 53 
1.8 Aims and objectives of the current study 51 
1.9 Study Outline 52 
CHAPTER TWO: MATERIALS AND METHODS  55 
2.1 Materials and Reagents 55 
2.2 Equipment and Apparatus 58 
2.3 Plant collection and authentication 60 
2.4 Plant extraction 60 
2.4.1 80% Ethanolic extract 60 
2.4.2 Hydrodistillation extract 60 
2.5 Characterization of A. crassna extract 61 
2.5.1 Fourier Transform Infrared Spectrometry 61 
2.5.2 Gas chromatography–mass spectrometer (GC–MS) 61 
2.5.3 Transmission Electron Microscopy 61 
2.6 Isolation of the active component 62 
2.6.1 Structure elucidation and characterization of the isolated 
compounds 63 
      2.6.1(a) FT-IR spectrometry 63 
      2.6.1(b) GC-MS analysis 63 
      2.6.1(c) Nuclear magnetic resonance (NMR) spectroscopy 64 
2.7 Cell lines and cell culture conditions 64 
2.8 Harvesting and counting of cells 65 
vii 
 
2.9 In vitro anticancer studies 65 
2.9.1 Cytotoxicity 66 
      2.9.1(a) Preparation of cells 66 
      2.9.1(b) Treatment of cells 66 
      2.9.1(c) Viability testing by MTT assay 66 
      2.9.1(d) Analysis of results 67 
2.9.2 Anti-Tumorigenicity 67 
      2.9.2(a) Clonogenicity 67 
      2.9.2(b) Cell migration 68 
      2.9.2(c) Cell invasion 69 
      2.9.2(d) Spheroid-based in vitro anti-tumor assay 69 
2.9.3 Apoptosis assays 70 
      2.9.3(a) Chromatin condensation and nuclear fragmentation 70 
      2.9.3(b) Loss of mitochondrial membrane potential 71 
      2.9.3(c) DNA fragmentation 71 
      2.8.3(d) Demonstration of apoptotic characteristics of HCT 116 cells by 
transmission electron microscope (TEM) 72 
      2.9.3(e) Apoptosis antibody array 73 
2.10 Antiangiogenic studies 74 
2.10.1 HUVECs proliferation assay 74 
2.10.2 Migration assay 75 
2.10.3 Tube formation assay 75 
2.10.4 Measuring VEGF expression in HUVECs lysates 76 
2.10.5 Ex vivo rat aortic ring assay 77 
       2.10.5(a) Experimental animals 77 
viii 
 
      2.10.5(b) Preparation of rat aortic segments into culturing plates 77 
      2.10.5(c) Treatment of rat aortic segments in culturing plates 78 
      2.10.5(d) Image analysis for quantification of neovascularization 78 
2.10.6 In vivo antiangiogenic study by CAM assay 79 
2.11 Toxicity Studies 80 
2.11.1 Experimental Animals 80 
2.11.2 Acute toxicity in mice 80 
2.11.3 Sub-acute toxicity in mice 81 
      2.11.3(a) Haematology indeces 82 
      2.11.3(b) Clinical biochemistry indexes 82 
      2.11.3(c) Histopathological study 82 
2.12 In vivo anti-tumor studies 83 
2.12.1 Experimental animals 83 
2.12.2 Ectotopic model 83 
      2.12.2(a) Preparation of HCT 116 cells 83 
      2.11.2(b) Establishment of subcutaneous tumors 83 
      2.12.2(c) Treatment and tumor size measurement 84 
      2.12.2(d) Euthanasia and tumor collection 84 
      2.12.2(e) Analysis of results 85 
2.12.3 Orthotropic Model 85 
      2.12.3(a) Establishment of xenografttumor model 85 
      2.12.3(b) Treatment and tumor size measurement 85 
      2.12.3(c) Analysis of results 86 
2.13 Statistical analysis 87 
 
ix 
 
CHAPERT THREE: INVESTIGATION OF CYTOTOXICITY   88 
3.1 Introduction 88 
3.2 Results 89 
3.2.1 Plant extraction 89 
3.2.2 Characterization of A. crassna essential oils by GC–MS 90 
3.2.3 Subcellular organization of A. crassna stem bark 93 
3.2.4 Anti-proliferative effect of A. crassna extracts 95 
3.2.5 Antiangiogenic effects of A. crassna extracts 99 
    3.2.5(a) Antiangiogenic effect in rat aortic model 99 
    3.2.5(b) Inhibition of tube formation 103 
3.3 Discussion 106 
3.4 Conclusion 109 
CHAPTER FOUR: IN VIVO TOXICOLOGY AND ANTI-TUMOR         110 
4.1 Introduction 110 
4.2 Results 111 
4.2.1 Acute toxicity study 111 
4.2.2 Sub-chronic toxicity study 111 
    4.2.2 (a) Hematological and biochemical parameters 112 
    4.2.2 (b) Morphological parameters 112 
4.2.3 In vivo antitumor study of A. crassna essential oils against 
colorectal cancer 113 
4.3 Discussion 124 
4.4 Conclusion 126 
 
x 
 
CHAPTER FIVE: APOPTOSIS MEDIATED ANTI-PROLIFERATIVE   127 
5.1 Introduction 127 
5.2 Results 128 
5.2.1 Isolation of the active principle 128 
5.2.2 Characterization of β-caryophyllene 130 
5.2.3 Inhibitory effect of β-caryophyllene on the proliferation of cancer 
cell lines 133 
5.3.3 β-Caryophyllene Inhibits Motility of  HCT 116 cells 138 
5.3.4 β-Caryophyllene Inhibits Invasion and Clonogenicity of HCT 116 
Cells 140 
5.3.5 β-Caryophyllene inhibits growth of tumor spheroids 142 
5.3.6 β-Caryophyllene induces chromatin condensation and DNA 
fragmentation in HCT 116 cells 144 
5.3.7 β-Caryophyllene reduces mitochondrial membrane potential in 
HCT-116 cells 146 
5.3.8 Observation of ultra-structural morphology of apoptotic HCT 116 
cells by TEM 148 
5.3.9 Effect of β-C on apoptotic markers 148 
5.4 Discussion 151 
5.5 Conclusion 155 
CHAPTER SIX: ANTI-ANGIOGENIC AND ANTI-TUMOR EFFECT   156 
6.1 Introduction 156 
6.2 Results 157 
6.2.1 Inhibition of cell proliferation and migration in HUVECs 157 
6.2.2 Inhibitory effect of β-C on tube formation of HUVECs 161 
xi 
 
6.2.3 Inhibition of VEGF expression 161 
6.2.4 Inhibitory effect of β-C on the microvessels of rat aorta 163 
6.2.5 In vivo chick chorioallantoic membrane (CAM) assay 163 
6.2.6 In vivo anti colorectal cancer activity of β-C 167 
    6.2.6(a) Ectopic model 167 
    6.2.6(b) Effect of β-C on orthotopic colorectal tumor growth 170 
6.3 Discussion 173 
    6.4 Conclusion                                                                                                          175 
CHAPTER SEVEN: GENERAL DISCUSSION  176 
CHAPTER EIGHT: CONCLUSION  195 
 
8.1 Summary 195 
8.2 Suggestions for future studies 197 
REFERENCES 198 
APPENDIX  241 
LIST OF CONFERENCES   
LIST OF PUBLICATIONS   
LIST OF AWARDS   
LIST OF PATENTS  
 
 
 
    
 
 
xii 
 
TABLE OF FIGURES 
Page 
Figure 1.1 The hallmarks of cancer 3 
Figure 1.2 The role of sprouting angiogenesis in tumor growth 13 
Figure 1.3 Morphological and biochemical changes during apoptosis, 
autophagy and   necrosis. 
22 
Figure 1.4 The extrinsic and the intrinsic pathways of apoptosis 29 
Figure 1.5 Possible multi-step scenario for colorectal cancer formation 35 
Figure 1.6 Chemical structures of selected anti-cancer compounds 
from different essential oil sources. 
44 
Figure 1.7 Aquilaria crassna tree, leaves, fruits, seeds and bark 49 
Figure 1.8 Schematic diagram of study outline 54 
Figure 3.1 GC-MS analysis of the essential oils of A. crassna  92 
Figure 3.2 Transmission electron microscopy imaging of  A. crassna 
stem bark  
94 
Figure 3.3 Selected cell lines 48 hours after treatment with  A. crassna 
extract 
97 
Figure 3.4 Dose dependent inhibitory effects of A. crassna extracts 
against tested cell lines 
98 
Figure 3.5 
 
Antiangiogenic effect of  A.crassna  hydrodistillation 
extract against microvessel sprouting in rat aortic explants  
100 
Figure 3.6  Graphical representation of antiangiogenic activity of 
hydrodistillation extract of  A.crassna   
            101 
Figure 3.7 Antiangiogenic activity of  A. crassna ethanol extract  
against microvessel sprouting in rat aortic explants 
102 
Figure 3.8 Dose-response relationship of  A. crassna extract as 
observed in tube formation assay 
 
104 
Figure 3.9 HUVECs matrigel tube formation upon treatment with A. 
crassna extract. 
 
105 
xiii 
 
Figure 4.1 Body weight changes of male (A) and female (B) Swiss 
mice during the 28-day toxicological assessment 
117 
Figure 4.2 Representative microscopic findings for the liver section of 
Swiss mice treated orally with 100 and 500 mg/kg essential 
oils 
118 
Figure 4.3 Representative microscopic findings for the kidney  section 
of Swiss mice treated orally with 100 and 500 mg/kg  
essential oils 
119 
Figure 4.4 Representative microscopic findings for the lung section of 
Swiss mice treated orally with 100 and 500 mg/kg essential 
oils 
120 
Figure 4.5 Representative microscopic findings for the spleen section 
of Swiss mice treated orally with 100 and 500 mg/kg 
essential oils EOs 
121 
Figure 4.6 The subcutaneous tumors in NCR nude mice 122 
Figure 4.7 Body weight and tumor size changes of nude mice during 
the 8 weeks of after treatment with the EOs extracts 
123 
Figure 5.1 Schematic diagram showing the bioassay (anti-proliferative 
assay)-guided isolation of β-caryophyllene from the 
essential oils of Aquilaria crassna 
129 
Figure 5.2 Fingerprints of β-caryophyllene (β-C) 132 
Figure 5.3 Effect of  β-C on the cellular morphology of human cancer 
and normal cell lines 
136 
Figure 5.4 Dose-dependent anti-proliferative effect of β-caryophyllene 
on human cancer and normal cell lines assessed by MTT-
assay 
137 
Figure 5.5 Anti-migratory effect of β-C against HCT 116 cells  139 
Figure 5.6 Photomicrographs of HCT 116 cells invading the matrigel 
barrier 
141 
Figure 5.7 Photomicrographs of Anti-tumor aggregation effects of β-C 
on in vitro HCT 116 cellular spheroids in a hanging drop 
assay. 
143 
Figure 5.8 Photomicrographs depicting images of HCT 116 cells with 
Hoechst 33258 Staining 
 
145 
Figure 5.9 Rhodamine 123 stained photomicrographic images of HCT 
116 cells 
147 
xiv 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 Ultrastructural micrographs using TEM showed further 
supportive information of the apoptotic features of β-C 
149 
Figure 5.11 Human antibody apoptotic protein array  150 
Figure 6.1 The effect of β-C on HUVEC morphology 158 
Figure 6.2 Dose-time response curve of β-C on cell migration assay 159 
Figure 6.3 Images of HUVECs migration assay 160 
Figure 6.4 Images of HUVECs Matrigel tube formation assay 162 
Figure 6.5 Graphical representation of the level of VEGF on untreated 
HUVEC cells and treated with β-C 
164 
Figure 6.6 Photomicrographs showing antiangiogenic effect of β-C 
against sprouting of microvessels in rat aortic explants 
165 
Figure 6.7 Effects of β-C on neovascularization in chorioallantoic 
membrane 
166 
Figure 6.8 The dose response relationship of β-C on tumor size of 
treated and untreated animals 
168 
Figure 6.9 Photographic image represents animals and their tumors 
with different doses of β-C 
169 
Figure 6.10 Photographic image represents anti-tumor activity of β-C. 
HCT 116 tumor implanted orthotopically in the cecal wall 
of nude mouse 
171 
Figure 6.11 Cross sections of orthotopic tumor tissue 172 
xv 
 
LIST OF TABLES 
Page 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1 Morphological and biochemical features of apoptosis 25 
Table 3.1 GC-MS quantitative analysis of phytochemicals of  A. 
crassna essential oils  
91 
Table 3.2 IC50 values of A. crassna extracts in various human cancer 
cell lines 
97 
Table 4.1  Effects of the sub chronic oral administration of EOs on 
hematological parameters in Swiss mice 
114 
Table 4.2 Effects of the sub chronic oral administration of EOs on 
hematological parameters in Swiss mice 
115 
Table 4.3 Effects of the subchronic oral administration of EOs on 
organ weights in Swiss mice 
116 
Table 5.1 IC50 values of β-caryophyllene on various human cancer 
cell lines 
134 
Table 5.2 Selectivity index of β-Caryophyllene which represents IC50 
for normal cell line/IC50 for cancerous cell line 
135 
   
   
xvi 
 
LIST OF ABBREVIATIONS 
 
˚C            Degree Celsius 
5-FU            5-Fluorouracil 
β-C                                    β-caryophyllene 
ALT                                  Alternative Lengthening of Telomeres 
APC            Adenomatous Polypsis Coli 
ATCC           American Type Culture Collection 
BA     Betulinic Acid 
Bad     Bcl-xL/Bcl2-associated death promoter 
Bax     Bcl2 associated X protein 
Bcl2     B-cell lymphoma 2 
Bcl-Xl    B-cell lymphoma extra large 
bFGF    Basic Fibroblast Growth Factor 
bp     Base Pair 
BER                                   Base-excision repair 
BSA     Bovine Serum Albumin 
CAM    Cellular adhesion molecules 
CCD-18Co    Normal human fibroblast 
CO2     Carbon dioxide 
DCM    Dichloromethane 
DMEM    Dulbecco's Modified Eagle's Medium 
DMSO    Dimethyl Sulfoxide 
DNA     Deoxyribonucleic Acid 
ECM     Extracellular Matrix 
EGF     Epidermal Growth Factor 
xvii 
 
EGFR    Epidermal Growth Factor Receptor 
ELISA    Enzyme linked immunosorbant assay 
EOs  Essential oils 
Fas            Tumor necrosis factor superfamily receptor 6 
FBS     Fetal Bovine Serum 
FDA     Food and Drug Administration 
FGF-2    Fibroblast Growth Factor-2 
FMT                                  Fluorescence Molecular Tomography 
FTIR             Fourier transforms infrared spectroscopy 
GCMS                                Gas Chromatography Mass Spectrometry 
HCT 116            Human colorectal carcinoma cell line 
HER-2            Human Epidermal growth factor Receptor 2 
HIF-1α            Hypoxia Inducible factor -1- alpha 
HIFs             Hypoxia Inducible Factors 
HSPs                                  Heat shock proteins 
HTRA                                High-temperature requirement factor 
HUVECs            Human umbilical vein endothelial cells 
IAP                                    Inhibitor Apoptotic Proteins 
IC50                    Median inhibitory concentration 
ICAM-1            Intercellular adhesion molecule-1 
IFN-α and γ           Interferons alpha and gamma 
Ig             Immunoglobulin 
IL             Interleukin 
INF      Interferon 
KBr     Potassium Bromide 
xviii 
 
K-ras     Kirsten-rat sarcoma virus 
K-ras/PI3-K   K-ras/Phosphatidylinositol 3-kinases 
K-ras/RAF    K-ras/Murine leukemia viral oncogene homolog 1 
K-ras/RAL    K-ras/ K-ras related protein 
LC50     Median lethal concentration 
LD50    Lethal Dose 50 
LPS     Lipopolysaccharide 
MAPK    Mitogen activated protein kinase 
MAPK    Mitogen-Activated Protein Kinase 
MAPK/ERK   MAPK-Extra cellular signal regulated enzyme kinase 
MAPK/JNK   Mitogen-Activated Protein Kinase/Jun N-terminal Kinase 
MCF-7    Human hormone sensitive and invasive breast cancer cell 
MEM    Minimum Essential Medium 
MeOH    Methyl alcohol 
MMPs    Matrix Metalloproteinase 
MMR Mismatch epair 
mTOR    Mammalian Target of Rapamycin 
MTT     Thiazolyl blue tetrazolium bromide 
NER                                  Nucleotide-excision repair 
NF-kB    Nuclear factor kappa B 
NIH     National Institutes of Health 
NMR    Nuclear magnetic resonance 
NO     Nitric Oxide 
OD     Optical density 
PBS     Phosphate buffered saline 
xix 
 
PDGFR    Platelets Derived Growth Factor Receptors 
PE     Plating Efficiency 
PPM     Part Per Million 
PS     Penicillin/Streptomycin 
SD     Standard Deviation 
SF     Survival Fraction 
SPF     Specific Pathogen Free 
STAT    Signal transducer and activator of transcription 
TGF     Tumor growth factor 
TGF-α    Transforming Growth Factor-alpha 
TGF-β    Transforming Growth Factor-beta 
TGFβR2    Transforming Growth Factor-β II Receptor 
TKI     Tyrosine Kinase Inhibitor 
TLC     Thin-layer chromatography 
TLRs     Toll like receptors 
TNF     Tumor necrosis factor 
VCAM-1    Vascular cell adhesion molecule-1 
VEGF    Vascular Endothelial Growth Factor 
VEGFR 1 and 2   Vascular Endothelial Growth Factor Receptors 1 and 2 
XIAP                                 X-linked inhibitor of apoptosis protein 
 
 
 
 
 
xx 
 
KAJAN ANTI-KANSER β-CARYOPHYLLENE, KOMPAUN 
SEMULAJADI DARIPADA AQUILARIA CRASSNA TERHADAP 
KANSER USUS 
 
ABSTRAK 
Aquilaria crassna (Thymelaeceae) telah digunakan dalam perubatan tradisional 
penduduk Asia untuk merawat jangkitan, penyakit kronik dan keradangan. Tumbuhan 
ini telah dilaporkan sebagai sumber yang kaya dengan komponen bioaktif. Dalam kajian 
ini, dua ekstrak disediakan daripada kulit batang A. crassna menggunakan etanol dan 
kaedah hidrolisasi. Minyak pati (EOs) yang diperoleh daripada kedua-dua ekstraksi 
diuji sitotoksisiti menggunakan empat jujukan sel kanser dan satu jujukan sel normal, 
termasuk HCT 116, PANC-1, MCF-7, PC 3 dan HUVECs. EOs daripada penyulingan 
hidro menunjukkan kesan sitotoksik yang sederhana tetapi terpilih terhadap sel HCT 
116 kanser usus dengan nilai IC50 28.0±1.5μg/mL. Seterusnya kesan EOs penyulingan 
hidro terhadap angiogenesis dikaji secara in vitro dan ex vivo dan EOs ditemui merencat 
secara langsung pembentukkan tiub endothelial dan percambahan salur mikro aorta 
tikus. Analisis fitokimia bagi EOs dijalankan mengguna spektometri TEM, FTIR, dan 
GC-MS telah menunjukkan kandungan yang tinggi β-caryophyllene, 1-
phenanthrenecarboxylic acid, dan α-caryophyllene, benzenedicarboxylic acid, azulene 
dan cyclodecene. Kajian toksikologi menunjukkan EOs mempunyai profil keselamatan 
yang baik dengan LD50 melebihi 2000 mg/mL. Kajian tumor xenograf bagi EOs 
menunjukkan aktiviti antikanser komponen ini terhadap kanser usus manusia adalah 
pada 200 mg/kg. Fraksinasi berpandukan bioaktiviti EOs terhadap jujukan – jujukan sel 
kanser menunjukkan β-caryophyllene (β-C) sebagai komponen bioaktif utama seperti 
yang dikenal pasti menggunakan FT-IR, NMS dan MS. Kajian sitotoksisiti 
xxi 
 
menunjukkan β-C mempunyai kesan anti proliferatif selektif terhadap sel kanser usus 
(IC50 19 µM). Komponen ini menyebabkan apoptosis, kondensasi nuklear, dan 
fragmentasi DNA yang mendedahkan badan apoptotik. Keputusan daripada ujian 
jajaran apoptotik antibodi manusia menunjukkan bahawa β-C menurunkan regulasi 
protin sel survival Survivin, HSPs, dan XIAP dan pada masa yang sama menaikkan 
regulasi penunjuk pro-apoptosis p21. β-C juga mempunyai kesan antiangiogenik dengan 
merencat migrasi sel endotelial, percambahan salur mikro aorta tikus, dan penyekatan 
faktor pertumbuhan endothelial vaskular (VEGF). β-C juga mempamerkan aktiviti anti 
tumor yang poten pada model xenograf ektopik dan ortotopik kanser usus, 
menyebabkan penurunan yang jelas dalam ketumpatan salur mikro dan peningkatan 
dalam apoptosis/ nekrosis tisu tumor. Keseluruhannya, dapat disimpulkan bahawa β-C 
menunjukkan aktiviti perencatan yang kuat terhadap pertumbuhan tumor usus melalui 
satu mekanisma yang melibatkan induksi apoptosis dan penyekatan angiogenesis.   
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ANTI-CANCER STUDIES OF β-CARYOPHYLLENE, A NATURAL 
COMPONENT ISOLATED FROM AQUILARIA CRASSNA ON 
COLORECTAL CANCER  
 
ABSTRACT 
Aquilaria crassna (Thymelaeceae) has been used in traditional Asian medicine to 
treat infections, chronic pain and inflammation. This plant has been reported as a rich 
source of bioactive constituents. In this study, two extracts were prepared from the stem 
bark of A. crassna using ethanol and hydrodistillation methods. The resulting essential 
oils (EOs) from both extraction approaches were subjected for cytotoxicity studies using 
four cancer cell lines and one normal cell line, namely HCT-116, PANC-1, MCF-7, PC 
3 and HUVECs. Hydrodistilled EOs displayed moderate cytotoxic effect but exhibited 
selectivity against colorectal cancer HCT-116 cells with the IC50 value (28.0 
±1.5μg/mL). Subsequently, the effect of hydrodistilled EOs on angiogenesis was 
investigated in vitro and ex vivo and it was found that EOs directly inhibits endothelial 
tube formation and sprouting of rat aorta microvessels. Phytochemical analysis of the 
EOs was carried out using TEM, FTIR, and GC-MS spectrometry revealing high 
amount of β-caryophyllene, 1-phenanthrenecarboxylic acid, and α-caryophyllene, 
benzenedicarboxylic acid, azulene and cyclodecene. Toxicology studies showed that the 
EOs had a good safety profile with LD50 being more than 2000 mg/ml. Xenograft tumor 
studies of EOs exhibits anticancer activity in dose-dependent manner towards human 
colorectal cancer at 50, 100 and 200 mg/kg. Bioactivity-guided fractionation of EOs 
towards cancer cell lines reveals β-caryophyllene (β-C) as a key bioactive compound as 
verified using FT-IR, NMR and MS. Cytotoxicity studies show that β-C has selective 
anti-proliferative effect towards colorectal cancer cells (IC50 = 19 μM). The compound 
xxiii 
 
causes apoptosis, nuclear condensation and DNA fragmentation revealing apoptotic 
bodies. Results of human antibody apoptotic array study demonstrated that β-C 
downregulates the cell survival proteins Survivin, HSPs and XIAP and at the same time 
upregulates the pro-apoptosis marker p21. β-C was also found to be strongly 
antiangiogenic by inhibiting endothelial cell migration, tube formation, sprouting of rat 
aorta microvessels and suppression of Vascular Endothelial Growth Factor (VEGF).  
β-C also exhibits potent anti-tumor activity in ectopic and orthotopic xenograft model of 
colorectal cancer causing clear decrease in microvessel density and increase in 
apoptosis/necrosis in tumor tissue. Overall, it can be concluded that β-C exhibits strong 
inhibitory activity against colorectal tumor growth through a mechanism that appears to 
involve apoptosis induction and angiogenesis suppression.   
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CHAPTER ONE : INTRODUCTION 
 
1.1 Cancer biology   
Cancer is the general name of a heterogeneous group of more than 100 diseases. It 
arises from dysregulation in normal cellular mechanisms; and it is characterized by 
alterations in the expression of multiple genes, leading to local tissue invasion, which 
may eventually turn into metastasis (Pecorino, 2012). It is widely accepted that 
tumorgenesis is a multistage-process. This suggestion has been supported by a vast 
array of experimental models, involving cell culture systems, animal models, and 
human subjects exposed to chemical or physical carcinogens (Pedraza-Fariña, 2006). 
Three distinct processes have been implicated in cancer development: The first, 
initiation, is highly associated with external carcinogenic agents causing DNA 
mutations and genetic damage to normal cells. Such damage may be irreversible if DNA 
does not undergo proper repair, leading to increased susceptibility of cancer formation 
(Sandoval and Esteller, 2012). The second, promotion, makes the major part of the 
latent period of carcinogenesis. It involves initiated cells undergoing gradual cell 
proliferation, leading to the emergence of uncontrolled growth and a malignant tumor 
(Vincent and Gatenby, 2008). The third, progression, represents the terminal stage and 
the end product of carcinogenesis. It is characterized by cell hyperproliferation and 
metastasis. In this stage, tumor cells undergo dissemination, and break away from their 
primary sites to invade nearby tissues via the circulatory system or a transport 
mechanism (Valastyan and Weinberg, 2011).  
Genes can be classified into three groups: gatekeepers, caretakers and landscapers 
(Michor et al., 2004): Gatekeepers are oncogenes and tumor suppressor genes which 
regulate proliferation and differentiation related pathways in the cell. Misregulation of 
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these genes may promote abnormal cell growth. In fact, gatekeeper gene P53 is the most 
commonly mutated gene in human cancers. About 50% of all human cancers are 
associated with structural alterations in TP53 alleles (Van Heems et al., 2007). 
Caretaker genes on the other hand prevent genomic instability in the cell. Genomic 
integrity is directly dependent on DNA repair mechanisms, such as mismatch repair 
(MMR), nucleotide-excision repair (NER) and base-excision repair (BER). Therefore, 
mutations in caretaker genes lead to accelerated transformation of a normal cell to a 
neoplastic one (Croc, 2008).  
Landscaper genes refer to those genes which organize cells‘ interactions with their 
surrounding microenvironment. Alterations in these genes do not directly affect cellular 
growth, but rather generate an abnormal environment which might allow carcinogenesis 
and cell transformation to ensue (Ashworth et al., 2011).  
    
1.2 Hallmarks of cancer  
During carcinogenesis, cells undergo a multistep process to acquire specific 
characteristics that can promote cancer development, including these six essential 
hallmarks: sustaining proliferative signaling, evading growth suppressors, evading 
programmed cell death (apoptosis), enabling replicative immortality, inducing 
angiogenesis, and activating invasion and metastasis. These six key features of cancer 
have been recently revised to add two more hallmarks: the ability to reprogram cell 
metabolism to generate adequate energy, and the ability to avoid immune destruction. 
Malignant growths are also believed to acquire additional characteristics which enable 
them to promote inflammation, and genome instability (Hanahan and Weinberg, 2000; 
Hanahan and Weinberg, 2011; Hanahan and Awada, 2012) (Fig 1.1).
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Figure 1.1: The Hallmarks of Cancer. A: The original six hallmark capabilities as 
described by Hanahan and Weinberg (2000). B: Emerging ‗hallmarks‘ and enabling 
characteristics. Adapted from Hanahan and Weinberg (2011). Reprinted with 
permission (License number 3446980210269), Elsevier Ltd. 
A 
B 
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1.2.1 Sustaining proliferative signalling  
During normal cell growth, differentiation and proliferation is regulated by growth 
signals. These stimulatory growth factors are carefully transmitted into the cell by 
components of the extracellular matrix; trans-membrane receptors; and intracellular 
signaling domains. Cancer cells, on the other hand, are able to sustain continuous 
proliferation by multiple ways. Some cancer cells produce their own growth factors, 
like tumor growth factor-α, and corresponding receptors via an autocrine stimulation 
process. This enables them to respond to their own growth factors in a positive feedback 
mechanism. Signaling cascades are deregulated in tumor cells, leading to 
overexpression of growth factors, which then bind to cell surface receptors making 
cancer cells hyper-responsive (Abbott et al., 2006; Hanahan and  Weinberg, 2011; 
Gutschner and Diederichs, 2012). Moreover, tumor cells can switch on extracellular 
matrix receptors, which would initiate the downstream pathways of these receptors, 
causing inappropriate cell behavior.  Ligand-activated growth signaling via integrins 
linked to components of the extracellular matrix can trigger SOS-Ras-Raf-MAP kinase 
pathways. These major cascades are vital to cancer cells growth. About 25% of all 
human tumors are associated with an altered structure of Ras proteins; and 40% of 
human melanomas are linked to mutations which affect the structure of Raf proteins 
(Hanahan and Weinberg, 2011).  
 
1.2.2 Evading growth suppressors 
In normal tissues, maintenance of cell proliferation, a state of quiescence, and tissue 
homeostasis is mediated by several antiproliferative growth signals. Such signals 
include soluble growth inhibitors, and immobilized inhibitors located in the 
extracellular matrix and on the surfaces of nearby cells (Gutschner and Diederichs, 
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2012). Cancer cells, however, escape growth suppression mechanisms. Many of the 
coding genes of tumor suppressing proteins, which operate in various ways to inhibit 
cell growth and proliferation, have been discovered by virtue of their physiological 
functions. Most of the antiproliferative signals are funneled through the retinoblastoma 
protein (pRb). In a hypophosphorylated state, pRb blocks proliferation by altering the 
function of a key transcription factor called E2F. This factor controls the expression of 
the genes necessary for cell cycle progression (Hanahan and Weinberg, 2011).  
Transforming growth factor-beta (TGF-β) is a distinctive anti-proliferative factor which 
prevents pRb from undergoing alteration or phosphorylation. TGF-β induces the 
expression of p21, a factor which blocks the phosphorylation of pRb by inhibiting the 
cyclin-dependent kinase (CDK) complexes that are responsible for pRb 
phosphorylation. Thus, disorders affecting the responsiveness of TGF-β may result in 
tumor development (Massague, 2008). 
 
1.2.3 Resisting cell death  
Normal cells have to maintain equilibrium between the net rates of proliferation, and 
cell death. Tumors can only develop once cells have managed to evade programmed cell 
death (Fulda et al., 2010). The apoptotic machinery comprises two main components: 
sensors and effectors. Sensors are cell surface receptors that bind to survival factors, 
such as IGF-1, IGF-2 and IL-3; and to the death factors conveyed by Fas ligands and 
TNF-α. Sensors are responsible for monitoring the extracellular and the intracellular 
environments. They respond to abnormalities, like DNA damage (Hanahan and 
Weinberg, 2000). On the other hand, apoptosis effectors‘ pathways involve the caspase 
family, which can be activated by Fas death receptors, or cytochrome C. However, 
tumor cells have developed strategies to avoid apoptosis. For instance, hypoxia, DNA 
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damage and oncogene over-expression can induce p53-dependent apoptosis (Harris, 
1996); however, many human tumors present an ability to inactivate p53 tumor 
suppressor gene. It has been estimated that about 2.4 million annual cancer cases 
worldwide are linked to p53 mutations (Richardson, 2013). 
  
1.2.4 Enabling replicative immortality 
In addition to avoiding anti-proliferative cell signaling pathways and generating self-
sufficient growth signals, tumor cells are not bound by the normal limits of cell 
replication. In contrast to normal cells, which have fixed lifespans, cancer cells undergo 
unlimited replication (Gutschner and Diederichs, 2012). As observed in normal cell 
culture systems, the replication potential of normal cells is normally limited by 
replicative senescence. A normal cell cannot have more than 50 to 70 divisions. 
Moreover, most normal human cells in the body suffer a systematic losts of telomeric 
DNA (repetitive DNA sequences in the form of TTAGGG repeats). It is estimated that 
with the duplication of each chromosome, about 50–100 base pairs are lost from the end 
of each telomere. Telomeres ultimately shorten to a critical length, which results in the 
loss of telomere protection, leading to chromosomal instability and loss of cell viability 
(Abbott et al, 2006; Meena et al, 2015). These limitations in cell replication act as 
barriers preventing normal cells from undergoing malignant transformation. Tumor 
cells have two mechanisms to circumvent the loss of telomeres: (I) They trigger 
telomerase expression to add telomeric repeats at the ends of chromosomes. (II) They 
undergo processes of Alternative Lengthening of Telomeres (ALT). Telomerase 
reactivation was observed in 90 % of all malignant tumors (Gutschner and Diederichs, 
2012); and the remaining 10 % of human malignant tumors have been found to utilize 
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ALT mechanisms for unlimited proliferation, and to achieve immortality (Lau et al, 
2013). 
 
1.2.5 Inducing angiogenesis 
The growth of new capillary blood vessels, referred to as angiogenesis, is an essential 
process in tumor progression that offers more nutrients and oxygen supplies.  Tumor 
mass formation would be limited to 1-2 mm
2
 if tumor cells could not undergo this fifth 
hallmark of cancer (Dimova at el, 2014). The formation of new blood vessels induced 
by tumor cells not only secures the supply of nutrients and oxygen but also allows 
tumors to secrete their toxic wastes and migrate to other sites (Gutschner and 
Diederichs, 2012). Angiogenesis is tightly regulated at the molecular level by way of a 
balance between inducing signals (bFGF and VEGF) and endogenous inhibitors 
(endostatin and angiostatin). However, an angiogenic switch is activated during tumor 
development, which leads to continuous formation of blood vessels to help nourish the 
tumor. To achieve sustained angiogenesis, tumor cells may overexpress inducing 
signals or downregulate endogenous inhibitors. An imbalance between inducers and 
inhibitors is a prominent feature of angiogenesis (Folkman, 2002). 
 
1.2.6 Tissue invasion and metastasis 
The final offstage in cancer development is known as metastasis; the diffusion of tumor 
cells from their primary sites to distant tissues. About 90 % of cancer-related deaths are 
attributable to metastasis, which occurs due to the systemic nature of cancer and the 
resistance of circulated cancer cells to current therapeutic approaches (Valastyan and 
Weinberg, 2011). Cancer invasion and metastasis are complicated processes: The initial 
steps of tissue invasion involve the activation of signal cascades that regulate 
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cytoskeletal dynamics, the turnover of the extracellular matrix, and cell-cell adhesion 
molecules (e.g., cadherin family) in tumor cells. Tissue invasion is followed by 
malignant cells migration to nearby tissue. Eventually, metastasis occurs as invading 
cancer cells connect to blood vessels; breakdown cellar membranes and endothelial 
walls; and disseminate through the circulatory system or other transport systems to 
colonize distant organs (Friedl and Alexander, 2011). 
 
1.2.7 Genomic instability and mutations 
Unlike normal tissues, the majority of human tumors are highly heterogeneous in nature 
because they arise from multiple clones of cancer cells as a consequence of genetic 
mutation(s), altered environmental conditions, and reversible changes in cell properties 
(Meacham and Morrison, 2013). The genetic integrity of non-cancerous cells is 
generally maintained by a highly coordinated process in which DNA replication is well 
systematized, with the overall probability of an error not exceeding a single base 
misalignment for every billion nucleotides. This high accuracy is owed to DNA 
polymerase, the enzyme that builds identical strands of DNA and ensures that the 
sequence remains immaculate (Loeb et al, 2003). Cytotoxic carcinogens can cause 
genetic instability by altering the cellular microenvironment, leading to the breakdown 
of essential components of the cell‘s genome maintenance machinery (Abbott et al, 
2006). Carcinogens may also cause epigenetic modifications i.e., changes affecting the 
functions of genes rather than their genetic structures (Kanwal and Gupta, 2012). 
Dysfunctional 'caretaker' genes contribute to accelerated accumulation of mutations. 
The products of these genes are responsible for detecting DNA damage and activating 
the repair machinery. They also work to inactivate mutagenic agents before any DNA 
damage occurs (Hanahan and Weinberg, 2011). Experimental studies estimate the 
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number of acquired genetic mutations in cancerous cells to be more than 10,000 (Loeb 
et al, 2003; Sieber et al, 2003). In fact, genomic instability is at the heart of all the 
stages of tumorgenesis, from pre-cancerous lesions to tissue invasion and metastasis 
(Negrini et al, 2010).  
 
1.2.8 Tumor-promoting inflammation  
Inflammation is the cornerstone of multiple cancer hallmarks. Inflammatory 
mechanisms can contribute to a stable tumor‘s microenvironment by providing 
bioactive molecules that maintain proliferative signaling (growth factors), limit 
apoptosis (survival factors), and promote angiogenesis (proangiogenic factors). 
Inflammation can also cause the recruitment of extracellular matrix constituents that 
facilitate invasion and metastasis (Hanahan and Weinberg, 2011). Tumor 
microenvironments contain many different inflammatory cells and mediators which 
increase the production of reactive oxygen species and lead to oxidative DNA damage, 
and a weakened DNA repair machinery. Actually, a normal inflammation is self-
limiting: It demonstrates active resolution via cell death and the clearance of metabolic 
wastes and immune cells. A chronic inflammation, on the other hand, is strongly 
associated with an increased risk of tumorgenesis. Approximately, 20 % of human 
tumors are associated with chronic inflammations caused by microbial infections, 
irritants or autoimmune diseases (Crusz and Balkwill, 2015). In reality, inflammation 
and tumor growth are two closely interrelated processes which enhance and facilitate 
one another. In certain type of cancers, inflammation can trigger the initiation process in 
cancer cells; and cancer cells can in return promote the inflammation further by 
enhancing the expression of proinflammatory transcription factors (NF-κB) and 
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inflammatory enzymes (COX-2). This gives rise to a rich and complex platform of 
inflammatory responses within the tumor‘s microenvironment (Mantovani et al. 2008).  
 
1.3 Angiogenesis 
The term of angiogenesis originates from two Greek words, ―angêion‖, which means 
vessel, and ―genesis‖ (birth or emergence). It has been used to refer to the formation of 
micro-vascular networks from preexisting vascular vessels (Ishak at el, 2014). 
Angiogenesis is a highly regulated physiological process. It is normally restricted to 
embryonic development, and is self-limiting in adults. During adulthood, it may be 
observed during wound healing or the female reproductive cycle. Pathological 
angiogenesis, however, is often associated with dysregulated growth factors and 
unstable blood vessels. It is destructive for the tissues and underlies the pathogenesis of 
many medical conditions, such as cancer, rheumatoid arthritis, obesity, asthma and 
diabetes (Carmeliet, 2005; Ellenberg et al, 2010). The role of angiogenesis in cancer 
development was controversial until 1971 when Judah Folkman, the ―father of 
angiogenesis,‖ proved that tumor growth was angiogenesis-dependent, as mentioned by 
Stephenson et al. (2013). Now, angiogenesis is regarded as one of the essential 
hallmarks of cancer and metastasis. It highlights the fact that tumors cannot grow 
beyond a few millimeters without sufficient oxygen and nutrients (Hanahan and 
Folkman, 1996; Hanahan and Weinberg, 2011). Since most solid tumors are reliant on 
neovascularization, angiogenesis related research has recently been invaluable to cancer 
therapy, because targeting tumor angiogenesis using antiangiogenic agents that inhibit 
or starve the growth of new blood vessels opens new avenues for the treatment of 
cancer. It has been estimated that more than 500 million people worldwide can benefit 
from antiangiogenic or proangiogenic   treatments (Carmeliet, 2005; Nassar et al, 2011).   
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1.3.1 Pathological angiogenesis 
Pathological and physiological angiogenesis processes utilize the same signaling 
pathways, featuring a cascade of highly coordinated cellular functions which drive the 
establishment of new blood vessels in response to an increasing demand for oxygen and 
nutrients. However, the main deference between the two is that pathological 
angiogenesis is persistent and irresolvable. Moreover, it is characterized by disorganized 
and tortuous vessel structures (Chung and Ferrara, 2011). Tumor vessels are often 
distinguishable from a physiological vasculature as their growth is driven by a tumor‘s 
microenvironment, which is rich in tumor secretory factors and predominated by 
hypoxia. In fact, hypoxia is responsible for triggering the ‗angiogenic switch‘ to allow a 
tumor to grow further and metastasize (Weis and Cheresh, 2011). Furthermore, tumor 
angiogenesis relies on four molecular mechanisms which contribute to tumor 
development: sprouting, intussusception, mimicry and co-option. 
 
1.3.1 (a) Sprouting angiogenesis 
The prominent strategy for tumor progression is sprouting angiogenesis, which allows 
tumors to grow beyond 2–3 mm3 in size (Fig 1.2). However, the initiation of the 
sprouting process requires a cascade of events which drive blood vessels to sprout. 
These events include the degradation of the endothelial basement membrane; the 
migration of endothelial cells into connective tissues; the activation of tip cells; and the 
proliferation of the stalk cells induced by certain  growth factors, like vascular 
endothelial growth factor-A (VEGF-A), fibroblast growth factor (FGF-2), and delta-like 
4 (Dll4). This is followed by the formation of solid sprouts of endothelial cells 
connected by complicated vascular loops (Li et al, 2014; Ribatti and Crivellato, 2012). 
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Furthermore, sprouting angiogenesis is an invasive process associated with extracellular 
proteolytic activities mediated by matrix metalloproteinases (MMPs). MMPs can 
degrade the constituents of the extra cellular matrix (ECM) and facilitate sustained 
sprouting (Ebrahem et al, 2010; Van Hinsbergh and Koolwijk, 2008).    
 
1.3.1 (b) Intussusceptive angiogenesis 
The term ―intussusception‖ is generally used to refer to the maturation of vascular 
networks through the formation of new blood vessels resulting from the insertion and 
extension of lumenal tissue pillars within the capillaries (Styp‐Rekowska et al, 2011). In 
contrast to sprouting, intussusception is a simple mechanism with a higher morphogenic 
potential, and fewer energetic and metabolic activities as it does not require cell 
proliferation, degradation of the basement membrane, migration or tube formation 
(Makanya et al, 2009). Additionally, intussusceptive angiogenesis not only relies on 
angiogenic growth factors but it is also stimulated by higher intra-vascular blood flow 
rates and/or higher levels of intra-vascular shear stress (Gianni-Barrera et al, 2011; 
Styp‐Rekowska et al, 2011).  
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Figure 1.2: The role of sprouting angiogenesis in tumor growth. (A) when a tumor volume is small, it can obtain oxygen and nutrients from 
existing local blood vessels (B) As the tumor grows beyond the capacity of local blood vessels, soluble pro-angiogenic factors are released to 
trigger the sprouting of new vessels from local existing ones (C) sprouting vessels provide a blood supply to the tumor; and this is required in 
order for the tumor to grow beyond 2–3 mm3 in size (Vasudev et al, 2014). 
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1.3.3 (c) Vasculogenic mimicry 
Vascular mimicry describes processes related to cell plasticity which occurs mainly in 
aggressive tumors, and in which tumor cells organize and mimic endothelial cells to 
make tube-like structures containing plasma and red blood cells without the 
participation of endothelial cells (Chung and Mahalingam, 2014). This phenomenon has 
been observed in several tumor types, and was described for the first time in malignant 
melanoma when tissue sections of uveal and cutaneous melanomas displayed patterns 
and networks of Schiff-acid-positive channels in the microcirculation of melanoma 
cells, which coincided with lower survival rates and poor prognosis (Hillen and 
Griffioen, 2007).  
 
1.3.3 (d) Vascular co-option 
Vessel co-option is an alternative mechanism that enables tumors to secure a supply of 
blood by hijacking existing vasculatures and facilitating tumor cells migration towards 
host blood vessels in well-vascularized organs, such as the brain, lungs, and liver 
(Donnem et al, 2013).  Vascular co-option has been implicated in 30 % of all colorectal 
cancer metastasis to the liver (Frentzas et al, 2014). In addition to being important in 
tumor development, vessel co-option has been associated with tumor aggressiveness 
and it is believed to be a factor in antiangiogenic drug resistance (Fidler and Kripke, 
2015).  
 
1.3.4 Vascular endothelial growth factor (VEGF) 
Seven members of the VEGF family have been identified so far, including the 
mammalian VEGF ligands, which comprise five glycoproteins: VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, and the placenta growth factor (PlGF). The other two members are 
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an analogous ligand found in the Orf viruses and known as VEGF-E; and an analogue in 
the snake venom of Trimeresurus flavoviridis known as VEGF-F. The activities of the 
VEGF family are mediated by three tyrosine kinase receptors: VEGFR1, VEGFR2, and 
VEGFR3 (Yamazaki et al, 2009; Zhuang and Ferrara, 2015). Each of the VEGF ligands 
demonstrates different binding specificity and affinity towards those VEGEF receptors. 
For example, VEGF-A, VEGF-B and PlGF tend to bind to VEGFR1; VEGF-A favors 
binding to VEGFR2; and VEGF-C and VEGF-D bind to VEGFR3. The proteolytic 
activities of VEGFC and VEGFD contribute to its affinity for VEGFR2 (Zhuang and 
Ferrara, 2015). Undoubtedly, the role of VEGFs in angiogenesis has been 
predominately the most researched in the field since the initial discovery of VEGFs. 
Findings in that capacity have provided significant insight into the mechanisms that 
underlie angiogenesis (Goel and Mercurio, 2013).  
Standing out in VEGF family, VEGF-A is considered to be the main stimulator of 
angiogenesis. It exerts it effect by activating VEGFR-1 and VEGFR-2, and is 
responsible for triggering many steps in the angiogenesis cascade of endothelial cells, 
such as proliferation, migration and survival,(Waldner et al, 2010). VEGF-A can be 
secreted by tumor cells and spread in the surrounding area, leading to substantial 
increase in vascular permeability due to activated VEGFR-2 (Shibuya, 2009). In 
addition to VEGF-A pro-angiogenic effect, it contributes to tumor-related 
immunosuppression by inhibiting the migration of T-lymphocytes to the tumor site and 
effecting the accumulation of immature dendritic cells (Voron et al, 2014). Unlike 
VEGF-A, VEGF-B does not have a pro-angiogenic activity. Its role in the molecular 
mechanisms of angiogenesis is poorly understood (Li et al, 2012). Nevertheless, recent 
studies have shown VEGF-B to be highly expressed in tumor tissue, contributing to 
tumor progression and poor prognosis (Lautenschlaeger et al, 2013; Angelescu et al, 
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2013). Other members of the VEGF family, like VEGF-C and VEGF-D, are known to 
be lymphangiogenic stimulators: They are over-expressed in various tumor types and 
act to promote lymph node invasion and metastasis (Kopfstein et al, 2007; Matsuura et 
al, 2009). Predominantly expressed in the placenta, but also detectable in the heart, 
lungs and skeletal muscles, placenta growth factor (PlGF) is known to be a factor in 
tumorigenesis. However, its role in tumor angiogenesis and progression remains poorly 
understood and controversial. On one hand, overexpression of PlGF in mouse 
melanoma has been linked to hypervascularization of the skin, a phenotype that is 
associated with tumor invasion and pulmonary metastases due to increased MMPs 
activation (Marcellini et al, 2006). On the other hand, PIGF was shown to suppress 
tumor growth in fibrosarcoma and Lewis lung carcinoma cell lines by remodeling and 
normalizing their respective vascular phenotypes, leading to significant reduction of 
tumor microvascular density and branch formation (Hedlund et al, 2009). Overall, 
VEGF-mediated signaling is key to various angiogenic processes in tumor cells, such as 
cell proliferation, migration and survival. It plays a vital role in tumor angiogenesis and 
progression. Hence, targeting VEGFs, their receptors and/or their downstream signals 
should precipitate tumor vessel regression and hinder tumor progression (Figg and 
Folkman, 2008; Goel and Mercurio, 2013). 
 
1.3.5 Antiangiogenic therapy  
In 1971, Judah Folkman hypothesized that angiogenesis did not initiate malignancy but 
rather promoted tumor growth and metastasis; and ever since, many attempts have been 
made to treat cancer by using therapeutic agents that disrupt tumor angiogenesis, acting 
in the developmental stage in particular (Kubota, 2012). Angiogenic inhibitors have 
been approved for use against many cancer types, such as hepatocellular carcinoma, 
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renal cell carcinoma, breast cancer and colorectal cancer (Sennino and McDonald, 
2012). The first proof of concept for an antiangiogenic approach was presented in the 
1990s as the effect of interferon alpha was demonstrated against angioblastoma. Later, 
thalidomide was shown to treat myeloma successfully in 1999. In February 2004, the 
Food and Drug Administration (FDA) approved the use of an antiangiogenic drug, 
Avastin® (Bevacizumab), for the treatment of metastatic colorectal cancer (Folkman, 
2004). With Avastin® reaping $2.5 billion in revenue in 2008, many pharmaceutical 
industries were encouraged to invest in the discovery of new angiogenic inhibitors 
(Moran, 2008). Until the year 2015, the (FDA) had approved up to 12 new 
antiangiogenic drugs: bevacizumab, sunitinib, sorafenib, regorafenib, pazopanib, 
vandetanib, cabozantinib, zivafl, ibercept, pegaptanib, ranibizumab and aflibercept 
(Zhuang and Ferrara, 2015). 
 
1.3.6 Mechanisms of antiangiogenic therapy 
In the last three decades, antiangiogenic therapy for cancer has gone from an interesting 
hypothesis to an accepted treatment approach for many cancer types. Mechanistically, 
antiangiogenic agents work by interfering with the key steps of angiogenesis. VEGF 
family plays key roles in the development and progression of many solid tumors. 
Understanding the molecular pathway of angiogenesis has been an essential step 
towards cancer treatment. Recently, several VEGFA-VEGFR2 blockers have been 
approved for clinical use in cancer (Duda, 2012). According to their mechanism of 
action, The National Cancer Institute classified antiangiogenic agents into three 
categories  including, agents  that directly inhibit endothelial cells (including integrin 
antagonists), agents capable of interfering with signaling cascades, and agents that 
inhibit the ability of endothelial cells to break down extracellular matrix (Al‐Husein et 
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al, 2012). Moreover, approved antiangiogenic agents can be classified into three major 
classes that target VEGF. 
 
1.3.6 (a) Anti-VEGF monoclonal antibodies  
Bevacizumab (Avastin, Genentech/Roche) is a recombinant humanized monoclonal 
antibody, emerged as the first effective antiangiogenic agents  that binds to all VEGFA 
isomers and neutralizes their activities by blocking the binding of VEGFA to VEGFR1 
and VEGFR2 (Zhuang et al, 2015). Despite the strong antitumor activity of 
bevacizumab, it does not provide robust benefit as a monotherapy in many advanced 
cancer cases, except glioblastoma and renal cell carcinoma (Arrillaga-Romany et al, 
2014). With the advantage of  exquisite selectivity for their target and longer half life, 
bevacizumab approved in combination with chemotherapy or cytokine therapy for 
several advanced metastatic cancers, including metastatic colorectal cancer, lung cancer, 
pancreatic cancer and metastatic breast cancer (Potente et al, 2011). However, the 
mechanistic basis of the interaction between Anti-VEGF antibody and chemotherapy is 
still elusive, and many proposed models need to be clinically validated (Ellis and 
Hicklin, 2008).       
 
1.3.6 (b) Small molecule inhibitors  
Sunitinib (Sutent, Pfizer) is an orally administered multi-TKI that targets VEGFR-1,-2,-
3, PDGFR, Flt-3 and RET. It was the first FDA approved agent for the management of 
gastrointestinal stromal tumor, and it is also approved for advanced renal cell 
carcinoma, metastatic pancreatic neuroendocrine tumors (Limaverde-Sousa et al, 2014). 
Although, it has been reported that sunitinib significantly targeted myeloid derived 
suppressor cells (MDSCs) and decrease their accumulation in the peripheral blood and 
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suppression metastatic renal cell carcomas. This reduction in immune suppression 
would be a rationale approach for sunitinib and immunotherapy combination for the 
treatment of certain tumor types (Finke et al, 2011). Recently, an extended- access trial 
in metastatic renal cell carcinoma has significantly provided considerable knowledge of 
the efficacy and safety of sunitinib and enabled 4543 patients with vast-ranging disease 
states to receive sunitinib treatment. The safety profile of sunitinib was consistent with 
the earlier reports, no unexpected long-term adverse events were seen, and clinical 
benefit was reported in all ages (Gore et al, 2015).  
Sorafenib (Nexavar, Bayer and Onyx) is a novel bi-aryal urea; it is also an orally 
administered multikinase inhibitor, with wide range of activity against RAFkinases and 
several receptor tyrosine kinases. Sorafenib targets VEGFR-2 and VEGFR-3, PDGFRb, 
Flt-3, and c-Kit (Ranieri et al, 2012). It has pronounce anti-tumor activity in in vitro 
studies, preclinical xenograft models of different potent cancer type including, colon, 
pancreatic, lung, renal and ovarian cancer. In addition, it is the only standard clinical 
treatment against advanced hepatocellular carcinoma (Chen et al, 2015). 
Axitinib (Inlyta, Pfizer) is a strong molecule inhibitor with selective specificity for 
VEGF-1, VEGF-2, and VEGF-3. In January 2012, axitinib received FDA approval for 
the treatment of renal cell carcinoma RCC (Al‐Husein et al, 2012). Besides the  potent 
antiangiogenic activity, axitinib have been reported to exhibit cytotoxic and 
immunomodulatory effects  via induces DNA damage and increase the expression of 
P21 in RCC cells,  which can be responsible for axitinib anti-tumor efficacy (Morelli et 
al, 2015).  
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1.3.6 (c) VEGF-Trap 
Aflibercept (Eylea, Regeneron and Bayer) is a VEGF decoy receptor, also known as 
VEGF-Trap, consisting of binding domains of VEGFR-1 and VEGFR-2 fused to the Fc 
portion of human immunoglobulin(Ig) gamma chain, which makes it a disulfide dimer 
(Zhuang et al, 2015). In November 2011, aflibercept was approved by the (FDA) for the 
treatment of   neovascular age-related macular degeneration (AMD), which is the 
leading cause of blindness among the old people (Stewart et al, 2012). In contrast to 
bevacizumab, which only binds to VEGFA isomers, aflibercept have a wider binding 
spectrum to VEGF-A, VEGF-B and PlGF, and it has a higher affinity for VEGFA than 
bevacizumab (Gaya and Tse, 2012).  However, several clinical studies supported further 
evaluation of aflibercept in combination with chemotherapy in various malignancies. 
Consequently, aflibercept showed significant improve the response rate of progression-
free survival (PFS) and overall survival (OS) in advanced colorectal cancer, whereas in 
advanced non-small-cell lung cancer it was found to improve the PFS but not OS 
(Limaverde-Sousa et al, 2014). 
 
1.4 Cell Death  
Cell death is an essential biological process of the normal embryological development, 
preservation of tissue homeostasis, morphogenesis and metamorphosis of multicellular 
organisms. In general, the number of cells in any tissue is controlled by an equilibrium 
process between cell proliferation and cell death. Imbalance of this control is an 
essential hallmark of cancer cells. However, mammalian cell death subdivided into 
three modes of death including apoptosis, autophagy and necrosis (Fig 1.3) which plays 
key roles in cell death decisions, based on morphological and biochemical differences. 
Apoptosis and autophagy are the two fundamental types of programmed cell death 
